Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report)'s stock price reached a new 52-week low during trading on Monday . The company traded as low as $7.54 and last traded at $7.66, with a volume of 139071 shares traded. The stock had previously closed at $8.07.
Analyst Upgrades and Downgrades
Several analysts have recently weighed in on the stock. The Goldman Sachs Group decreased their target price on shares of Day One Biopharmaceuticals from $39.00 to $27.00 and set a "buy" rating on the stock in a research report on Tuesday, March 25th. Bank of America decreased their price objective on Day One Biopharmaceuticals from $28.00 to $25.00 and set a "buy" rating on the stock in a report on Tuesday, January 7th. HC Wainwright reissued a "buy" rating and issued a $36.00 target price on shares of Day One Biopharmaceuticals in a report on Thursday. Wedbush reaffirmed an "outperform" rating and issued a $32.00 price target on shares of Day One Biopharmaceuticals in a research note on Wednesday, February 26th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $32.00 price target on shares of Day One Biopharmaceuticals in a research report on Wednesday, February 26th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $32.29.
View Our Latest Research Report on Day One Biopharmaceuticals
Day One Biopharmaceuticals Trading Down 6.4 %
The stock has a fifty day moving average of $10.23 and a two-hundred day moving average of $12.44. The stock has a market capitalization of $731.78 million, a price-to-earnings ratio of -7.01 and a beta of -1.38.
Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last announced its earnings results on Tuesday, February 25th. The company reported ($0.69) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.34). The firm had revenue of $29.21 million during the quarter, compared to the consensus estimate of $27.11 million. Equities analysts expect that Day One Biopharmaceuticals, Inc. will post -0.72 earnings per share for the current year.
Insider Buying and Selling at Day One Biopharmaceuticals
In related news, CEO Jeremy Bender sold 12,048 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total value of $144,094.08. Following the completion of the sale, the chief executive officer now owns 128,015 shares of the company's stock, valued at $1,531,059.40. This trade represents a 8.60 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Charles N. York II sold 4,370 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total transaction of $52,265.20. Following the completion of the transaction, the chief financial officer now owns 252,638 shares of the company's stock, valued at $3,021,550.48. This trade represents a 1.70 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 21,064 shares of company stock worth $251,925. 8.40% of the stock is currently owned by corporate insiders.
Institutional Trading of Day One Biopharmaceuticals
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DAWN. GF Fund Management CO. LTD. acquired a new position in Day One Biopharmaceuticals during the 4th quarter valued at about $27,000. R Squared Ltd acquired a new position in Day One Biopharmaceuticals in the fourth quarter valued at approximately $31,000. Tower Research Capital LLC TRC boosted its stake in Day One Biopharmaceuticals by 911.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 10,657 shares of the company's stock valued at $135,000 after acquiring an additional 9,603 shares during the last quarter. E Fund Management Co. Ltd. acquired a new stake in Day One Biopharmaceuticals during the 4th quarter worth $143,000. Finally, KLP Kapitalforvaltning AS bought a new stake in shares of Day One Biopharmaceuticals during the 4th quarter valued at $150,000. 87.95% of the stock is currently owned by institutional investors and hedge funds.
About Day One Biopharmaceuticals
(
Get Free Report)
Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.
Featured Stories
Before you consider Day One Biopharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Day One Biopharmaceuticals wasn't on the list.
While Day One Biopharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
